USD 4.33
(1.64%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 12.52 Million USD | -26.82% |
2022 | 22.3 Million USD | -69.41% |
2021 | 72.91 Million USD | 165.98% |
2020 | 27.41 Million USD | 193.06% |
2019 | -29.45 Million USD | 42.86% |
2018 | -51.55 Million USD | -1022.78% |
2017 | -4.59 Million USD | -2300.23% |
2016 | 208.69 Thousand USD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | 8.9 Million USD | -260.64% |
2024 Q1 | -3.85 Million USD | -693.53% |
2023 Q1 | -3.97 Million USD | -195.56% |
2023 FY | 16.32 Million USD | -26.82% |
2023 Q4 | 649 Thousand USD | -91.94% |
2023 Q3 | 8.05 Million USD | -17.39% |
2023 Q2 | 9.74 Million USD | 344.97% |
2022 Q2 | 11.93 Million USD | 1268.69% |
2022 Q1 | 872 Thousand USD | -95.74% |
2022 FY | 22.3 Million USD | -69.41% |
2022 Q4 | 4.16 Million USD | 134.01% |
2022 Q3 | 1.77 Million USD | -85.09% |
2021 Q2 | 23.58 Million USD | 86.96% |
2021 FY | 72.91 Million USD | 165.98% |
2021 Q1 | 12.61 Million USD | -42.05% |
2021 Q4 | 20.45 Million USD | 25.74% |
2021 Q3 | 16.26 Million USD | -31.05% |
2020 Q2 | -2.25 Million USD | 85.07% |
2020 FY | 27.41 Million USD | 193.06% |
2020 Q4 | 21.77 Million USD | -5.26% |
2020 Q3 | 22.98 Million USD | 1120.43% |
2020 Q1 | -15.08 Million USD | -759.98% |
2019 Q1 | -12.12 Million USD | -170.56% |
2019 FY | -29.45 Million USD | 42.86% |
2019 Q4 | -1.75 Million USD | 78.78% |
2019 Q3 | -8.26 Million USD | -12.93% |
2019 Q2 | -7.31 Million USD | 39.62% |
2018 Q3 | -2.24 Million USD | -138.61% |
2018 Q4 | -4.48 Million USD | -99.2% |
2018 FY | -51.55 Million USD | -1022.78% |
2018 Q1 | -1.15 Million USD | 10.74% |
2018 Q2 | -942.52 Thousand USD | 18.67% |
2017 Q2 | -221.8 Thousand USD | -1.45% |
2017 Q3 | -2.85 Million USD | -1186.31% |
2017 FY | -4.59 Million USD | -2300.23% |
2017 Q4 | -1.29 Million USD | 54.5% |
2017 Q1 | -218.64 Thousand USD | -222.73% |
2016 FY | 208.69 Thousand USD | 0.0% |
2016 Q2 | -500.00 USD | 96.78% |
2016 Q4 | 178.15 Thousand USD | 1329.34% |
2016 Q3 | -14.49 Thousand USD | -2798.4% |
2016 Q1 | -15.55 Thousand USD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Collegium Pharmaceutical, Inc. | 166.96 Million USD | 92.498% |
Embecta Corp. | 221.5 Million USD | 94.345% |
ANI Pharmaceuticals, Inc. | 46.97 Million USD | 73.335% |
Dynavax Technologies Corporation | -37.02 Million USD | 133.826% |
Esperion Therapeutics, Inc. | -155.56 Million USD | 108.051% |
Pacira BioSciences, Inc. | 87.67 Million USD | 85.714% |
PainReform Ltd. | -9.58 Million USD | 230.687% |
Aquestive Therapeutics, Inc. | -15.1 Million USD | 182.936% |
Sunshine Biopharma, Inc. | -4.78 Million USD | 361.739% |
SCYNEXIS, Inc. | 72.66 Million USD | 82.764% |
China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 597.969% |
Cosmos Health Inc. | -21.83 Million USD | 157.372% |
Journey Medical Corporation | -2.07 Million USD | 704.197% |
Sunshine Biopharma, Inc. | -4.78 Million USD | 361.739% |
Safety Shot Inc | -12.18 Million USD | 202.797% |
Alpha Teknova, Inc. | -35.56 Million USD | 135.219% |
Intra-Cellular Therapies, Inc. | -159.38 Million USD | 107.859% |
Bright Green Corporation | -8.89 Million USD | 240.867% |
Procaps Group, S.A. | 38.97 Million USD | 67.862% |
Theratechnologies Inc. | -10.62 Million USD | 217.86% |
Harrow Health, Inc. | 580 Thousand USD | -2059.483% |
Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 366.433% |
Biofrontera Inc. | -22.67 Million USD | 155.232% |
DURECT Corporation | -36.88 Million USD | 133.958% |
Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 337.711% |
Cronos Group Inc. | -81.37 Million USD | 115.392% |
OptiNose, Inc. | -22.74 Million USD | 155.06% |
Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 94.008% |
Kala Pharmaceuticals, Inc. | -39.15 Million USD | 131.99% |
RedHill Biopharma Ltd. | 12.63 Million USD | 0.847% |
Guardion Health Sciences, Inc. | -4.33 Million USD | 388.84% |
Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 301.664% |
Radius Health, Inc. | -3.92 Million USD | 419.108% |
Universe Pharmaceuticals INC | -3.52 Million USD | 455.14% |
ProPhase Labs, Inc. | -21.61 Million USD | 157.951% |
Phibro Animal Health Corporation | 53.31 Million USD | 76.508% |
Procaps Group S.A. | 52.32 Million USD | 76.063% |
Alvotech | -354.86 Million USD | 103.53% |
TherapeuticsMD, Inc. | -8.52 Million USD | 246.955% |
Viatris Inc. | 766.2 Million USD | 98.365% |
Rockwell Medical, Inc. | -6.67 Million USD | 287.781% |
Aytu BioPharma, Inc. | -5.25 Million USD | 338.39% |
SIGA Technologies, Inc. | 83.62 Million USD | 85.022% |
Tilray Brands, Inc. | -174.74 Million USD | 107.168% |
Lifecore Biomedical, Inc. | 9.33 Million USD | -34.23% |
Shineco, Inc. | -17.06 Million USD | 173.392% |
PetIQ, Inc. | 60.01 Million USD | 79.13% |
Regencell Bioscience Holdings Limited | -4.73 Million USD | 364.423% |
Incannex Healthcare Limited | -30.04 Million USD | 141.693% |
Neurocrine Biosciences, Inc. | 250.9 Million USD | 95.008% |
Alimera Sciences, Inc. | -1.47 Million USD | 951.462% |
Silver Spike Investment Corp. | 7.34 Million USD | -70.638% |
Assertio Holdings, Inc. | -243.53 Million USD | 105.143% |
Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 312.563% |
Petros Pharmaceuticals, Inc. | -13.61 Million USD | 191.978% |
Clever Leaves Holdings Inc. | -15.59 Million USD | 180.319% |
Cyclo Therapeutics, Inc. | -20.05 Million USD | 162.469% |
Avadel Pharmaceuticals plc | -137.84 Million USD | 109.086% |
Hempacco Co., Inc. | -8.81 Million USD | 242.131% |
Talphera, Inc. | -16.88 Million USD | 174.161% |
Alvotech | -354.86 Million USD | 103.53% |
Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 76.569% |
Lantheus Holdings, Inc. | 364.64 Million USD | 96.565% |
Currenc Group, Inc. | -6.64 Million USD | 288.465% |
Kamada Ltd. | 10.06 Million USD | -24.453% |
Indivior PLC | -4 Million USD | 413.125% |
Evoke Pharma, Inc. | -7.43 Million USD | 268.553% |
Flora Growth Corp. | -50.35 Million USD | 124.874% |
Cyclo Therapeutics, Inc. | -20.05 Million USD | 162.469% |
Evolus, Inc. | -49.23 Million USD | 125.44% |
HUTCHMED (China) Limited | 18.37 Million USD | 31.837% |
Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 93.642% |
Akanda Corp. | -10.05 Million USD | 224.61% |